Synonyms: 4F-Benzoyl-TN14003 | Aphexda® | BKT140 | BL-8040 | TF14016 [4]
motixafortide is an approved drug (FDA (2023))
Compound class:
Peptide
Comment: Motixafortide (BL8040) is a CXCR4 antagonist that is being developed by Biokine Therapeutics [1]. It is a 14-residue polypeptide modified from a naturally occurring horseshoe crab protein. Motixafortide acts as an inverse agonist in [35S]GTPγS binding assays [1]. It induces safe and efficient stem cell mobilisation in MM patients in preparation for autologous stem cell transplantation [3], and it is being proposed as a mechanism to improve anti-tumour immune reponse against solid tumours [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
For advanced searching click here to open chemical structure editor
Other Similar Sequences ![]() |
|
TC14012 |
TargetsACKR3 |